During the year, the Company settled all ongoing litigation with Warner Chilcott's for its oral contraceptive products Loestrin® 24 Fe and Femcon® Fe. In addition, Warner Chilcott has granted Lupin a non-exclusive license covering Femcon® Fe, which will permit Lupin to commence marketing either an authorized generic product, which would be supplied by Warner Chilcott, or a generic equivalent of Femcon® Fe in the United States. Warner Chilcott has also granted Lupin the rights to purchase and sell in the US an authorised generic version of its Asacol® 400 mg (Mesalamine tablets) product. The Company also settled all ongoing litigation over Eszopiclone tablets thereby dismissing a patent suit brought by the drug's manufacturer Dainippon Sumitomo Pharma Co., Ltd's subsidiary Sunovion Pharmaceuticals Inc. ("Sunovion"). In addition, the Company settled separate patent infringement suits brought by Abbott Laboratories and ElanPharma International Ltd. over Lupin's efforts to market a generic version of cholesterol drug TriCor® (Fenofibrate) tablets.
During the year, the Company also entered into a license agreement with Abbott Laboratories and Laboratoires Fournier S.A. for various Abbott patents for Lupin's Antara® (Fenofibrate) Capsules. During the course of the year, Lupin filed 75 Formulation patents, 42 API / Process patents and 17 NCE patents.